mc receptor

Nonapeptide-1 (Melanostatine™ 5) can inhibit the synthesis of melanin, which makes it of interest for treating certain skin conditions.

α-MSH (MSH, amide) is amide stimulates melanocortin 1 receptor that results in the activation of adenylyl cyclase.

MCL0020 is a potent and selective melanocortin MC4 receptor antagonist (IC50 values are 11.63, 1115, and >10,000 nM at MC4, MC3, and MC1 receptors, respectively). It significantly reverses stress-induced anorexia without affecting food intake in free-feeding rats and exhibits anxiolytic-like activity in vivo.

Acetyl-ACTH (4-24) (human, bovine, rat), a proopiomelanocortin (POMC) peptide fragment, functions as an agonist at the MC-1 receptor [1]. This compound encompasses a sequence present in adrenocorticotrophin (ACTH), the precursor for α-MSH, illustrating its significant role in the POMC peptide family.

HS024 is a highly potent melanocortin MC4 receptor antagonist (Ki values are 0.29, 18.6, 5.45 and 3.29 nM for cloned human MC4, MC1, MC3 and MC5 receptors respectively). Increases food intake, and blocks α-MSH- and MTII-induced hypotension and bradycardia in rats, following central administration in vivo.

Melanotan I is a non-specific melanocortin receptor (MCR) agonist, an α-melanocyte-stimulating hormone (α-MSH) analog, which is injected subcutaneously to increase the amount of melanin in the skin Melanotan I is used as an adjunct to tanning Melanotan I has been used for the prevention of sunlight-induced skin cancers Melanotan I has been used in the study of melanoma and for male erectile dysfunction Melanotan I may be used to prevent sun-induced skin cancer and may be used to study melanoma and male erectile dysfunction.

Melanocortin (MC) 3-MSH (Melanocyte-Stimulating Hormone) is believed to signal through the MC 3 receptor. It induces a sustained increase in intracellular free calcium levels ([Ca2+]i) in a subpopulation of pituitary cells. Most of the cells responding to

Adrenocorticotropic Hormone (ACTH) (4-10) is a potent agonist of the melanocortin receptor (MC4R).

Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.

(p-Iodo-Phe7)-ACTH (4-10), a derivative of adrenocorticotrophic hormone (ACTH) produced by the anterior pituitary gland, functions as a melanocortin (MC) receptor antagonist and effectively inhibits α-melanocyte-stimulating hormone (α-MSH)-induced excessive grooming behavior in rats [1].

Acetyl-ACTH (3-24) (human, bovine, rat), a segment derived from the proopiomelanocortin (POMC) peptide, functions as an agonist at the MC-1 receptor [1]. Encompassing adrenocorticotrophin (ACTH), a precursor to α-MSH, it illustrates its role within the spectrum of POMC peptides.

Acetyl-ACTH (2-24) (human, bovine, rat), a proopiomelanocortin (POMC) peptide fragment, includes adrenocorticotrophin (ACTH) precursor of α-MSH and serves as an agonist at the MC-1 receptor [1].